Standard HPV Vaccine Dose May Be More Protective Than Reduced Dose
Young women and girls who receive a single dose of the human papillomavirus (HPV) vaccine were at significantly higher risk of abnormal cervical pathology compared with women who received 2 doses, according to the results of a recent study.
In order to evaluate the long-term effects of various HPV vaccine doses, researchers conducted an analysis of health insurance claims from 11,335 young women, aged 9 to 26 years, who had received at least 1 dose of HPV vaccination.
Could the HPV Vaccine Help Treat Recurrent Oral Warts?
ACS Update Recommendations for HPV Vaccine in Children 9 to 14 Years Old
Overall, 1975 of the 11,335 young women received 1 dose of the vaccine (group 1), 2089 received 2 doses (group 2), and 7271 received 3 doses (group 3). After roughly 5 years of follow-up, participants in group 1 had a higher cumulative incidence of high-grade cytology or histology, adenocarcinoma in situ, and cervical cancer compared with individuals in group 2. However, no significant differences were noted between groups 2 and 3.
“Our results show that women who received 2 doses of the HPV vaccine exhibit higher prophylactic efficacy against abnormal high-grade cytology, high-grade histology, adenocarcinoma in situ, and invasive cervical cancer when compared to women who received a single dose. However, no additional protective effect was found with getting a third dose of the HPV vaccine,” the researchers concluded.
Zeybek B, Rodriguez A. Comparison of long term impact and clinical outcomes of reduced dose vs. standard dose quadrivalent human papillomavirus vaccine in the United States: A database study [Presented at the Society of Gynecologica Oncology’s Annual Meeting on Women’s Cancer]. National Harbor, MD. March 12, 2017.